Cronin Owen, Subedi Deepak, Forsyth Laura, Goodman Kirsteen, Lewis Steff C, Keerie Catriona, Walker Allan, Porteous Mary, Cetnarskyj Roseanne, Ranganath Lakshminarayan R, Selby Peter L, Hampson Geeta, Chandra Rama, Ho Shu, Tobias Jon H, Young-Min Steven A, McKenna Malachi J, Crowley Rachel K, Fraser William D, Tang Jonathan, Gennari Luigi, Nuti Rannuccio, Brandi Maria-Luisa, Del Pino-Montes Javier, Devogelaer Jean-Pierre, Durnez Anne, Isaia Giovanni Carlo, Di Stefano Marco, Rubio Josep Blanch, Guanabens Nuria, Seibel Markus J, Walsh John P, Kotowicz Mark A, Nicholson Geoffrey C, Duncan Emma L, Major Gabor, Horne Anne, Gilchrist Nigel L, Ralston Stuart H
Rheumatic Diseases Unit, Western General Hospital, Edinburgh, UK.
Department of Radiology and Nuclear Medicine, Western General Hospital, Edinburgh, UK.
J Bone Miner Res. 2020 Jul;35(7):1246-1252. doi: 10.1002/jbmr.4007. Epub 2020 Apr 20.
Mutations in SQSTM1 are strongly associated with Paget's disease of bone (PDB), but little is known about the clinical characteristics of those with early disease. Radionuclide bone scans, biochemical markers of bone turnover, and clinical characteristics were analyzed in SQSTM1 mutation carriers who took part in the Zoledronic acid in the Prevention of Paget's disease (ZiPP) study. We studied 222 individuals, of whom 54.9% were female, with mean ± SE age of 50.1 ± 0.6 years. Twelve SQSTM1 mutations were observed, including p.Pro392Leu, which was present in 141 of 222 (63.5%) subjects. Bone scan examination revealed evidence of PDB in 20 subjects (9.0%), ten of whom (50%) had a single affected site. Participants with lesions were older than those without lesions but the difference was not significant (53.6 ± 9.1 versus 49.8 ± 8.9; p = .07). The mean age of participants with lesions was not significantly different from the age at which their parents were diagnosed with PDB (55 years versus 59 years, p = .17). All individuals with lesions were asymptomatic. Serum concentrations of total alkaline phosphatase (ALP) normalized to the upper limit of normal in each center were higher in those with lesions (0.75 ± 0.69 versus 0.42 ± 0.29 arbitary units; p < .0001). Similar findings were observed for other biochemical markers of bone turnover, but the sensitivity of ALP and other markers in detecting lesions was poor. Asymptomatic PDB is present in about 9% of SQSTM1 mutation carriers by the fifth decade. Further follow-up of this cohort will provide important information on the natural history of early PDB and its response to treatment. © 2020 The Authors. Journal of Bone and Mineral Research published by American Society for Bone and Mineral Research.
SQSTM1基因的突变与骨Paget病(PDB)密切相关,但对于疾病早期患者的临床特征却知之甚少。对参与唑来膦酸预防Paget病(ZiPP)研究的SQSTM1突变携带者的放射性核素骨扫描、骨转换生化标志物及临床特征进行了分析。我们研究了222名个体,其中54.9%为女性,平均年龄±标准误为50.1±0.6岁。观察到12种SQSTM1突变,其中p.Pro392Leu突变存在于222名受试者中的141名(63.5%)。骨扫描检查发现20名受试者(9.0%)有PDB证据,其中10名(50%)只有一个受累部位。有病变的参与者比无病变的参与者年龄大,但差异不显著(53.6±9.1岁与49.8±8.9岁;p = 0.07)。有病变参与者的平均年龄与他们父母被诊断为PDB时的年龄无显著差异(55岁与59岁,p = 0.17)。所有有病变的个体均无症状。各中心总碱性磷酸酶(ALP)血清浓度校正至正常上限后,有病变者更高(0.75±0.69与0.42±0.29任意单位;p < 0.0001)。骨转换的其他生化标志物也有类似发现,但ALP和其他标志物检测病变的敏感性较差。到五十岁时,约9%的SQSTM1突变携带者存在无症状PDB。对该队列的进一步随访将为早期PDB的自然史及其对治疗的反应提供重要信息。© 2020作者。由美国骨与矿物质研究学会出版的《骨与矿物质研究杂志》